Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2116455 | Cancer Letters | 2010 | 7 Pages |
Abstract
Cucurbitacin B is an anti-cancer drug candidate and its efficacy has been demonstrated in hepatocellular carcinoma (HCC). To explore its mechanism against HCC, BEL-7402 cells were treated with cucurbitacin B in vitro. Treatment with cucurbitacin B induced S phase arrest and apoptosis. The growth inhibition effect was associated with cyclin D1 and cdc-2 down regulations. Western blotting analysis of cell signaling molecules indicated that cucurbitacin B inhibited c-Raf activation without affecting STAT3 phosphorylation. Moreover, in vivo study demonstrated that cucurbitacin B is effective against BEL-7402 xenograft when administrated orally.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kin Tak Chan, Fan Yan Meng, Qian Li, Cheong Yip Ho, Tsz Shan Lam, Yu To, Wai Him Lee, Miao Li, Kee Hung Chu, Melvin Toh,